Vermillion Cuts Q2 Loss by 35 Percent | GenomeWeb
NEW YORK (GenomeWeb News) – Vermillion today reported a 35 percent improvement for its second-quarter net loss but no revenues for the three months ended June 30, 2008.
 
The company’s net loss shrank to $4.5 million, or $.70 per share, from $6.8 million, or $1.74 per share, in the second quarter of 2007.
 
Earnings-per-share calculations for both years account for the 10-for-one reverse stock split that the company enacted in March.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.